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Poster Session II S331Results: Liver stiffness was significantly correlated with thalassemia
classification (p 5 0.001), iron deposition (p 5 0.003) and fibrosis
stage (p\0.001).MedianTE values were significantly different in pa-
tients with severe fibrosis (stage 3-5) 4.5 (60.8 SD) kPa from those
with mild or no fibrosis (stage 0-2) 3.9 (62.8 SD) kPa (p 5 0.000).
The AUROC for prediction of high fibrosis stages (3-5) was 0.802
(95% confidence interval [CI]: 0.665-0.938) with cut-off of 4.35
kPa with 81.8% sensitivity (95% CI: 52.3-94.9) and 70.0% specific-
ity (95% CI: 52.1-83.3).
Conclusion: Our results demonstrate that transient elastography is
a reliable non-invasive tool to evaluate liver iron content and fibrosis
in patients with b-thalassemia major who are candidates for hemato-
poietic stem cell transplantation and can be an alternative to liver bi-
opsy. Moreover, it is a valuable tool to follow-up the liver status in
patients with b-thalassemia major after transplantation.342
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR SECOND-
ARY ACUTE MYELOID LEUKEMIA EVOLVING FROM MYELODYSPLASTIC
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Background: Secondary acute myeloid leukemia (AML) evolving
from myelodysplastic syndrome (MDS) is associated with a poor
prognosis and long-term survival is expected in only a small propor-
tion without allogeneic hematopoietic cell transplantation (HCT).
Methods:Weevaluated clinical outcomes of 37 consecutive patients
who underwent allogeneic HCT for secondary AML evolving from
MDS between January 1997 and April 2010 in a single institute. We
also tried to identify prognostic factors for the outcomes.
Results:Median age of the patients, 22 males and 15 females, was 46
years (range, 25-70). Median duration from diagnosis of MDS to
AML evolution was 2.8 months (range, 0.2-31.0). Before evolution
to AML, MDS was treated with hypomethylating agents in 11 pa-
tients, intensive chemotherapy in 1, and supportive care only in 25.
Twenty-six patients received induction chemotherapy for AML evo-
lution and 14 of them (54%) attained complete remission (CR). All
patients were well engrafted at a median day 15 (range, 6-39).
Nine of 37 patients (24.3%) developed acute GVHD and 13 of 26
assessable patients (50.0%) developed chronic GVHD. After a me-
dian follow-up duration of 38.0 months (range, 4-164), 18 patients
died of disease progression or recurrence (n 5 10) or non-relapse
causes (n 5 8). The 3-year probabilities of overall survival (OS), re-
lapse-free survival (RFS), and non-relapse mortality (NRM) were
47%, 65%, and 24%, respectively. Multivariate analyses revealed
that female sex (vs. male; HR, 4.6; p5 0.006), reduced-intensity con-
ditioning regimen (vs. myeloablative; HR, 4.0; p5 0.030), and hypo-
methylating therapy or intensive chemotherapy for MDS (vs.
supportive care only; HR, 3.7; p5 0.012) were independently unfa-
vorable prognostic factors for OS; shorter duration (\ 4 months)
from AML evolution to HCT (vs. $ 4 months; HR, 0.245; p 5
0.047) and reduced-intensity conditioning regimen (vs. myeloabla-
tive; HR, 6.1; p 5 0.040) were unfavorable prognostic factors for
RFS; there was no independent prognostic factor for NRM. Patients
who developed acute GVHD showed a trend for superior RFS (p 5
0.058), but inferior NRM (p 5 0.127). Patients who developed
chronic GVHD had higher OS (p 5 0.006) and RFS (p 5 0.031).
Conclusions: Allogeneic HCT was an effective therapy for second-
ary AML evolving fromMDS. Clinical outcomes were inferior with
reduced-intensity conditioning than myeloablative conditioning.
Presence of graft-versus-leukemia effects was evident.343
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Donor availability can be a significant obstacle to allogeneic
blood or marrow transplantation (BMT). Single- and multi-center
studies have shown that partially HLA-mismatched (haploidentical)
bone marrow from family members is a suitable source of donor
cells, thus extending this potentially curative treatment to patients
who lack HLA-matched donors. Use of PBPC instead of marrow
for haploidentical transplantation may allow wider applicability of
this approach but there is concern about risk of acute and chronic
GvHD due to the 5-10-fold higher number of T-cells in the
allograft.
We report preliminary results on 14 patients with HL or NHL
and 4 patients with MDS or leukemia (median age 51 yr) who re-
ceived allogeneic transplantation of T-replete PBPC from haploi-
dentical donors at our two centers. We used the protocol
reported by Brunstein, et al. (Blood 118:282 [2011]) except that
PBPC were substituted for bone marrow as the graft source. RIC
consisted of 30 mg/m2/d of fludarabine on days -6 to -2, 14.5
mg/kg/d of cyclophosphamide on days -6 and -5 and 200 cGy
TBI on day -1. PBPC were mobilized and collected in the standard
manner. GvHD prophylaxis included post-transplant cyclophos-
phamide (50 mg/kg/d on days +3 and +4) followed on day +5 by
standard dosing of tacrolimus and mycophenolate. The median
number of HLA-mismatches in the HvG and GvH directions
were 5 and 4, respectively. Allografts contained a median of 6 x
106 CD34 cells/kg and 18 x 107 CD3 cells/kg. Median times to
neutrophil and platelet recovery were 16 and 17 d, respectively.
One patient (6%) rejected their graft and recovered autologous he-
matopoiesis. All other recipients were 100% donor chimeras by day
+28. Grade II acute GvHD was observed in 11 of 16 (69%) evalu-
able patients and Grade III GvHD was observed in one patient
(6%). No chronic GvHD by NIH criteria was observed in patients
who survived beyond day +100. Three of 18 (16%) patients died of
non-relapse causes, all due to infection. Median follow-up of sur-
viving patients is short. Six patients have relapsed (4 of 14 lympho-
mas including 3 patients with ATLL and 1 of 4 patients with
myeloid malignancies). Our results suggest that PBPC can be
substituted for marrow as the donor source in haploidentical trans-
plantation with low rates of rejection, acute and chronic GvHD and
NRM that are similar to those observed after transplantation of
haploidentical bone marrow using this protocol.344
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The CIBMTR is conducting a non-inferiority study of IV busul-
fan-based conditioning regimens vs. traditional ablative cyclophos-
phamide and TBI in patients (pts) with myeloid malignancies
undergoing related or unrelated SCT. Of 1750 pts, we describe
the practices and outcomes of chimerism testing in 155 pts who re-
ceived RIC in this study. 7 had no chimerism testing; data is avail-
able on 140 pts. A total of 807 chimerism assays were performed.
Initial chimerism testing was most commonly performed at day
30 (95/140pts) while only a small percentage had their first chime-
rism ./ 5 90 days post-SCT (19/140pts). Chimerism testing was
performed at a median of 3 (1-6) time points with a median of 5
(1-24) separate assays per patient. Multiple cell types (at least 3
types) were assayed (e.g. BM +/- PB MNC +/- lymphocytes +/- lin-
eage specific cells) in 45 pts, often at one time point. Other com-
mon patterns of testing in a single episode of care were BM +
PBMC (n32), PBMC only (n23), PB T and B cells (n18), BM
only (n13) and other combinations (n9). In 62 instances chimerism
was performed on the BM and PB at the same time. BM chimerism
differed by \10% from PBMC in 21, myeloid cells in 15 and T
